{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T23:33:58Z","timestamp":1791588838571,"version":"4.3.4"},"reference-count":130,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T00:00:00Z","timestamp":1750464000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB-TRR 338"],"award-info":[{"award-number":["SFB-TRR 338"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["452881907"],"award-info":[{"award-number":["452881907"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007277","name":"Icahn School of Medicine at Mount Sinai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007277","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["2R01DK128289"],"award-info":[{"award-number":["2R01DK128289"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002745","name":"Bavarian Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002745","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jhep.2025.06.007","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T02:32:28Z","timestamp":1750386748000},"page":"1156-1171","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Chimeric antigen receptor (CAR) T-cell therapy: Engineering immune cells to treat liver diseases"],"prefix":"10.1016","volume":"83","author":[{"given":"Elmar","family":"Jaeckel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1178-6195","authenticated-orcid":false,"given":"Scott L.","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hudecek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9421-1911","authenticated-orcid":false,"given":"Ulrike","family":"Protzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2025.06.007_bib1","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1172\/JCI119308","article-title":"Cytotoxic T cells and viral hepatitis","volume":"99","author":"Chisari","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhep.2025.06.007_bib2","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jhep.2021.11.021","article-title":"The quest for precision oncology with immune checkpoint inhibitors for hepatocellular carcinoma","volume":"76","author":"Cabibbo","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.06.007_bib3","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jhep.2010.10.025","article-title":"Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines","volume":"55","author":"Gehring","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.06.007_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0182936","article-title":"Isolation and functional characterization of hepatitis B virus-specific T-cell receptors as new tools for experimental and clinical use","volume":"12","author":"Wisskirchen","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2025.06.007_bib5","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/hep.31502","article-title":"Targeting tumor-associated antigens in hepatocellular carcinoma for immunotherapy: past pitfalls and future strategies","volume":"73","author":"Lu","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.06.007_bib6","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/0006-291X(87)90502-X","article-title":"Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions","volume":"149","author":"Kuwana","year":"1987","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jhep.2025.06.007_bib7","doi-asserted-by":"crossref","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2025.06.007_bib8","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/0092-8674(91)90314-O","article-title":"The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways","volume":"64","author":"Irving","year":"1991","journal-title":"Cell"},{"key":"10.1016\/j.jhep.2025.06.007_bib9","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/mt.2009.83","article-title":"Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo","volume":"17","author":"Milone","year":"2009","journal-title":"Mol Ther"},{"key":"10.1016\/j.jhep.2025.06.007_bib10","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/nbt0102-70","article-title":"Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta\/CD28 receptor","volume":"20","author":"Maher","year":"2002","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jhep.2025.06.007_bib11","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.jcyt.2024.02.024","article-title":"Alternative target recognition elements for chimeric antigen receptor (CAR) T cells: beyond standard antibody fragments","volume":"26","author":"Nix","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jhep.2025.06.007_bib14","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1038\/leu.2017.57","article-title":"Fully human CD19-specific chimeric antigen receptors for T-cell therapy","volume":"31","author":"Sommermeyer","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.jhep.2025.06.007_bib130","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1158\/1078-0432.CCR-13-0330","article-title":"Receptor affinity and extracellular domain modifications affect tumor recognition by ROR-1-specific chimeric antigen receptor T cells","volume":"19","author":"Hudecek","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhep.2025.06.007_bib12","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/PPO.0000000000000036","article-title":"Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition","volume":"20","author":"Riddell","year":"2014","journal-title":"Cancer J (Sudbury, Mass)"},{"key":"10.1016\/j.jhep.2025.06.007_bib13","doi-asserted-by":"crossref","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jhep.2025.06.007_bib15","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/leu.2015.247","article-title":"Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo","volume":"30","author":"Sommermeyer","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.jhep.2025.06.007_bib16","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1182\/blood-2011-07-366419","article-title":"Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells","volume":"119","author":"Terakura","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jhep.2025.06.007_bib17","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2025.06.007_bib18","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2025.06.007_bib19","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2025.06.007_bib20","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1038\/s41591-024-02986-9","article-title":"Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study","volume":"30","author":"Morschhauser","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2025.06.007_bib21","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2025.06.007_bib22","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2025.06.007_bib23","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2025.06.007_bib24","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41591-018-0290-5","article-title":"Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency","volume":"25","author":"Feucht","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2025.06.007_bib25","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.abe2606","article-title":"Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function","volume":"14","author":"Salter","year":"2021","journal-title":"Sci signaling"},{"key":"10.1016\/j.jhep.2025.06.007_bib26","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jhep.2025.06.007_bib27","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/s41571-022-00607-3","article-title":"Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion","volume":"19","author":"Amini","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jhep.2025.06.007_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1303935","article-title":"Lymphodepletion - an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle","volume":"14","author":"Lickefett","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhep.2025.06.007_bib29","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.cell.2015.03.005","article-title":"Immunosurveillance of the liver by intravascular effector CD8(+) T cells","volume":"161","author":"Guidotti","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.jhep.2025.06.007_bib30","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/hep.27376","article-title":"Liver sinusoidal endothelial cells in hepatic fibrosis","volume":"61","author":"DeLeve","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.06.007_bib31","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aba2351","article-title":"Immune surveillance of the liver by T cells","volume":"5","author":"Ficht","year":"2020","journal-title":"Sci Immunol"},{"key":"10.1016\/j.jhep.2025.06.007_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1289303","article-title":"CAR Immunotherapy for the treatment of infectious diseases: a systematic review","volume":"15","author":"Morte-Romea","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhep.2025.06.007_bib33","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adj6251","article-title":"Enhancing the safety of CAR T cell therapy: synthetic genetic switch for spatiotemporal control","volume":"10","author":"Lu","year":"2024","journal-title":"Sci Adv"},{"key":"10.1016\/j.jhep.2025.06.007_bib34","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13045-021-01128-9","article-title":"IL-7 and CCL19-secreting CAR T cell therapy for tumors with positive glypican-3 or mesothelin","volume":"14","author":"Pang","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jhep.2025.06.007_bib35","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1053\/j.gastro.2007.11.002","article-title":"T cells redirected against hepatitis B virus surface proteins eliminate infected hepatocytes","volume":"134","author":"Bohne","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.06.007_bib36","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.jhep.2021.06.022","article-title":"T-cell engager antibodies enable T cells to control HBV infection and to target HBsAg-positive hepatoma in mice","volume":"75","author":"Quitt","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.06.007_bib37","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.virol.2023.06.015","article-title":"PreS1- targeting chimeric antigen receptor T cells diminish HBV infection in liver humanized FRG mice","volume":"586","author":"Guo","year":"2023","journal-title":"Virology"},{"key":"10.1016\/j.jhep.2025.06.007_bib38","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.omtm.2021.10.012","article-title":"Characterization of a library of 20 HBV-specific MHC class II-restricted T cell receptors","volume":"23","author":"Schreiber","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jhep.2025.06.007_bib39","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1136\/gutjnl-2014-308316","article-title":"Chimeric antigen receptor (CAR)-engineered T cells redirected against hepatitis C virus (HCV) E2 glycoprotein","volume":"65","author":"Sautto","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2025.06.007_bib40","doi-asserted-by":"crossref","DOI":"10.1111\/cmi.13399","article-title":"Hepatitis B virus envelope proteins can serve as therapeutic targets embedded in the host cell plasma membrane","volume":"23","author":"Zhao","year":"2021","journal-title":"Cell Microbiol"},{"key":"10.1016\/j.jhep.2025.06.007_bib41","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1053\/j.gastro.2013.04.047","article-title":"T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice","volume":"145","author":"Krebs","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.06.007_bib42","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1053\/j.gastro.2015.09.026","article-title":"Interferon-gamma and tumor necrosis factor-alpha produced by T cells reduce the HBV persistence form, cccDNA, without cytolysis","volume":"150","author":"Xia","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.06.007_bib43","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/hep4.1857","article-title":"Immunological alterations after immunotherapy with short lived HBV-TCR T cells associates with long-term treatment response in HBV-HCC","volume":"6","author":"Tan","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2025.06.007_bib44","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/s41586-024-07630-7","article-title":"A liver immune rheostat regulates CD8 T cell immunity in chronic HBV infection","volume":"631","author":"Bosch","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2025.06.007_bib45","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2014.10.001","article-title":"Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient","volume":"62","author":"Qasim","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.06.007_bib46","doi-asserted-by":"crossref","first-page":"735","DOI":"10.3350\/cmh.2024.0058","article-title":"Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting","volume":"30","author":"Wan","year":"2024","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jhep.2025.06.007_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.918869","article-title":"The tumor microenvironment of hepatocellular carcinoma and its targeting strategy by CAR T cell immunotherapy","volume":"13","author":"Guizhen","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jhep.2025.06.007_bib48","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2025.06.007_bib49","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.06.007_bib50","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41577-021-00574-3","article-title":"CD8(+) T cell differentiation and dysfunction in cancer","volume":"22","author":"Philip","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jhep.2025.06.007_bib51","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41571-024-00932-9","article-title":"Tumour mutational burden: clinical utility, challenges and emerging improvements","volume":"21","author":"Budczies","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jhep.2025.06.007_bib52","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/hep.31279","article-title":"Targeting neoantigens in hepatocellular carcinoma for immunotherapy: a futile strategy?","volume":"73","author":"Lu","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.06.007_bib124","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1846926","article-title":"Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase II trial","volume":"9","author":"Dai","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jhep.2025.06.007_bib125","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1089\/hum.2018.229","article-title":"Preclinical evaluation of chimeric antigen receptor-modified T cells specific to epithelial cell adhesion molecule for treating colorectal cancer","volume":"30","author":"Zhang","year":"2019","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jhep.2025.06.007_bib126","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/CJI.0000000000000460","article-title":"Development of engineered CAR T cells targeting tumor-associated glycoforms of MUC1 for the treatment of intrahepatic cholangiocarcinoma","volume":"46","author":"Mao","year":"2023","journal-title":"J Immunother"},{"key":"10.1016\/j.jhep.2025.06.007_bib127","doi-asserted-by":"crossref","first-page":"4810","DOI":"10.1038\/s41467-020-18444-2","article-title":"Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma","volume":"11","author":"Tseng","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhep.2025.06.007_bib128","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7555\/JBR.35.20200207","article-title":"c-Met-targeted chimeric antigen receptor T cells inhibit hepatocellular carcinoma cells in vitro and in vivo","volume":"36","author":"Huang","year":"2021","journal-title":"J Biomed Res"},{"key":"10.1016\/j.jhep.2025.06.007_bib57","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1038\/s41591-023-02612-0","article-title":"CLDN6-specific CAR T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial","volume":"29","author":"Mackensen","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2025.06.007_bib58","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1126\/science.aay5967","article-title":"An RNA vaccine drives expansion and efficacy of claudin-CAR T cells against solid tumors","volume":"367","author":"Reinhard","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.jhep.2025.06.007_bib53","doi-asserted-by":"crossref","first-page":"6418","DOI":"10.1158\/1078-0432.CCR-14-1170","article-title":"Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma","volume":"20","author":"Gao","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhep.2025.06.007_bib54","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/s41586-024-08261-8","article-title":"Interleukin-15-armored GPC3-CAR T cells for patients with solid cancers","volume":"637","author":"Steffin","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2025.06.007_bib120","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1016\/S2352-3026(24)00273-4","article-title":"Accelerating and optimising CAR T-cell manufacture to deliver better patient products","volume":"12","author":"Agliardi","year":"2025","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jhep.2025.06.007_bib102","doi-asserted-by":"crossref","first-page":"4216","DOI":"10.1016\/j.cell.2023.08.013","article-title":"Modular pooled discovery of synthetic knockin sequences to program durable cell therapies","volume":"186","author":"Blaeschke","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.jhep.2025.06.007_bib129","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.4_suppl.TPS624","article-title":"A phase I study of GPC3 targeted CAR T cell therapy in advanced GPC3-expressing hepatocellular carcinoma (HCC)","volume":"41","author":"Xie","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2025.06.007_bib55","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","article-title":"Hepatocellular carcinoma","volume":"400","author":"Vogel","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2025.06.007_bib56","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/imr.12125","article-title":"Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma","volume":"257","author":"Chmielewski","year":"2014","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jhep.2025.06.007_bib59","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","article-title":"Mechanisms of hepatic stellate cell activation","volume":"14","author":"Tsuchida","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.06.007_bib60","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/s41575-023-00821-z","article-title":"Friend or foe? The elusive role of hepatic stellate cells in liver cancer","volume":"20","author":"Cogliati","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.06.007_bib61","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41586-022-05289-6","article-title":"Opposing roles of hepatic stellate cell subpopulations in hepatocarcinogenesis","volume":"610","author":"Filliol","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2025.06.007_bib62","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41586-020-2403-9","article-title":"Senolytic CAR T cells reverse senescence-associated pathologies","volume":"583","author":"Amor","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2025.06.007_bib63","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jhep.2024.03.014","article-title":"Phenotypes and ontogeny of senescent hepatic stellate cells in metabolic dysfunction-associated steatohepatitis","volume":"81","author":"Yashaswini","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.06.007_bib64","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41586-019-1546-z","article-title":"Targeting cardiac fibrosis with engineered T cells","volume":"573","author":"Aghajanian","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2025.06.007_bib65","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jcmgh.2022.12.005","article-title":"Fibroblast activation protein activates macrophages and promotes parenchymal liver inflammation and fibrosis","volume":"15","author":"Yang","year":"2022","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.06.007_bib66","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1002\/hep.510290631","article-title":"Fibroblast activation protein: a cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis","volume":"29","author":"Levy","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.06.007_bib67","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1038\/nbt.3386","article-title":"GFP-specific CD8 T cells enable targeted cell depletion and visualization of T-cell interactions","volume":"33","author":"Agudo","year":"2015","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jhep.2025.06.007_bib68","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.adf6696","article-title":"Hepatic stellate cells maintain liver homeostasis through paracrine neurotrophin-3 signaling that induces hepatocyte proliferation","volume":"16","author":"Trinh","year":"2023","journal-title":"Sci Signal"},{"key":"10.1016\/j.jhep.2025.06.007_bib69","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/s43587-023-00560-5","article-title":"Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction","volume":"4","author":"Amor","year":"2024","journal-title":"Nat Aging"},{"key":"10.1016\/j.jhep.2025.06.007_bib70","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.06.007_bib71","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-Targeted CAR T cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2025.06.007_bib72","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2025.06.007_bib73","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up","volume":"390","author":"Muller","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2025.06.007_bib74","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","article-title":"CAR T-cell therapy in autoimmune diseases","volume":"402","author":"Schett","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2025.06.007_bib75","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/hep.32134","article-title":"Quantification of polyreactive immunoglobulin G facilitates the diagnosis of autoimmune hepatitis","volume":"75","author":"Taubert","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.06.007_bib76","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1111\/liv.15970","article-title":"Rituximab is a safe and effective alternative treatment for patients with autoimmune hepatitis: results from the ColHai registry","volume":"44","author":"Riveiro-Barciela","year":"2024","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2025.06.007_bib77","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.jhepr.2019.10.005","article-title":"Efficacy of rituximab in difficult-to-manage autoimmune hepatitis: results from the international autoimmune hepatitis group","volume":"1","author":"Than","year":"2019","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2025.06.007_bib78","article-title":"Belimumab is a promising third-line treatment option for refractory autoimmune hepatitis","volume":"2","author":"Arvaniti","year":"2020","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2025.06.007_bib79","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.jhep.2025.06.007_bib80","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1084\/jem.184.2.387","article-title":"Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation","volume":"184","author":"Asano","year":"1996","journal-title":"J Exp Med"},{"key":"10.1016\/j.jhep.2025.06.007_bib81","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad4134","article-title":"Type 1 diabetes immunotherapy using polyclonal regulatory T cells","volume":"7","author":"Bluestone","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jhep.2025.06.007_bib82","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/hep.26380","article-title":"Genetic predisposition and environmental danger signals initiate chronic autoimmune hepatitis driven by CD4+ T cells","volume":"58","author":"Hardtke-Wolenski","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.06.007_bib83","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jhepr.2019.08.001","article-title":"Liver homing of clinical grade Tregs after therapeutic infusion in patients with autoimmune hepatitis","volume":"1","author":"Oo","year":"2019","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2025.06.007_bib84","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abo2628","article-title":"Selective decrease of donor-reactive T(regs) after liver transplantation limits T(reg) therapy for promoting allograft tolerance in humans","volume":"14","author":"Tang","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jhep.2025.06.007_bib85","doi-asserted-by":"crossref","first-page":"306","DOI":"10.2337\/diabetes.54.2.306","article-title":"Antigen-specific FoxP3-transduced T-cells can control established type 1 diabetes","volume":"54","author":"Jaeckel","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.jhep.2025.06.007_bib86","doi-asserted-by":"crossref","first-page":"3619","DOI":"10.1172\/JCI33185","article-title":"Conferring indirect allospecificity on CD4+CD25+ Tregs by TCR gene transfer favors transplantation tolerance in mice","volume":"118","author":"Tsang","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhep.2025.06.007_bib87","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1084\/jem.20040139","article-title":"In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes","volume":"199","author":"Tang","year":"2004","journal-title":"J Exp Med"},{"key":"10.1016\/j.jhep.2025.06.007_bib88","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1002\/eji.201344381","article-title":"Isolation of human antigen-specific regulatory T cells with high suppressive function","volume":"44","author":"Noyan","year":"2014","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jhep.2025.06.007_bib89","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10991","article-title":"Type 1 diabetes vaccine candidates promote human Foxp3(+)Treg induction in humanized mice","volume":"7","author":"Serr","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhep.2025.06.007_bib90","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz3866","article-title":"Functional effects of chimeric antigen receptor co-receptor signaling domains in human regulatory T cells","volume":"12","author":"Dawson","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jhep.2025.06.007_bib91","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/ajt.14175","article-title":"Prevention of allograft rejection by use of regulatory T cells with an MHC-specific chimeric antigen receptor","volume":"17","author":"Noyan","year":"2017","journal-title":"Am J Transpl"},{"key":"10.1016\/j.jhep.2025.06.007_bib92","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/ajt.14185","article-title":"Expression of a chimeric antigen receptor specific for donor HLA class I enhances the potency of human regulatory T cells in preventing human skin transplant rejection","volume":"17","author":"Boardman","year":"2017","journal-title":"Am J Transpl"},{"key":"10.1016\/j.jhep.2025.06.007_bib93","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1172\/JCI82771","article-title":"Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor","volume":"126","author":"MacDonald","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhep.2025.06.007_bib94","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/hep4.1807","article-title":"The detrimental role of regulatory T cells in nonalcoholic steatohepatitis","volume":"6","author":"Dywicki","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2025.06.007_bib95","article-title":"Advancing CD19 CAR T cell therapy for treatment of primary biliary cholangitis","volume":"212","author":"Sokke","year":"2024","journal-title":"J Immunol"},{"key":"10.1016\/j.jhep.2025.06.007_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102888","article-title":"Forced Fox-P3 expression can improve the safety and antigen-specific function of engineered regulatory T cells","volume":"132","author":"McGovern","year":"2022","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jhep.2025.06.007_bib97","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1005582","article-title":"Membrane-bound IL-2 improves the expansion, survival, and phenotype of CAR Tregs and confers resistance to calcineurin inhibitors","volume":"13","author":"Kremer","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhep.2025.06.007_bib98","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn1716","article-title":"Pancreatic islet-specific engineered T(regs) exhibit robust antigen-specific and bystander immune suppression in type 1 diabetes models","volume":"14","author":"Yang","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jhep.2025.06.007_bib99","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41586-019-1054-1","article-title":"CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape","volume":"568","author":"Hamieh","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2025.06.007_bib100","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1038\/s41590-020-0786-2","article-title":"BATF3 programs CD8(+) T cell memory","volume":"21","author":"Ataide","year":"2020","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jhep.2025.06.007_bib101","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","article-title":"c-Jun overexpression in CAR T cells induces exhaustion resistance","volume":"576","author":"Lynn","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2025.06.007_bib103","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1038\/s41467-018-05395-y","article-title":"The chimeric TAC receptor co-opts the T cell receptor yielding robust anti-tumor activity without toxicity","volume":"9","author":"Helsen","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhep.2025.06.007_bib104","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1038\/s41467-019-10097-0","article-title":"Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response","volume":"10","author":"Baeuerle","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhep.2025.06.007_bib105","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1038\/s41467-019-10948-w","article-title":"Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR T","volume":"10","author":"Nerreter","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhep.2025.06.007_bib106","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/s43018-025-00927-0","article-title":"Sensitive bispecific chimeric T cell receptors for cancer therapy","volume":"6","author":"Simon","year":"2025","journal-title":"Nat Cancer"},{"key":"10.1016\/j.jhep.2025.06.007_bib107","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1146\/annurev-med-042921-024719","article-title":"Multispecific CAR T cells deprive lymphomas of escape via antigen loss","volume":"74","author":"Furqan","year":"2023","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.jhep.2025.06.007_bib108","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1182\/blood.2022015795","article-title":"CD19\/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR","volume":"140","author":"Shalabi","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jhep.2025.06.007_bib109","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1158\/2159-8290.CD-23-0101","article-title":"Programming CAR T cell tumor recognition: tuned antigen sensing and logic gating","volume":"13","author":"Hamieh","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jhep.2025.06.007_bib110","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41591-021-01621-1","article-title":"HLA-independent T cell receptors for targeting tumors with low antigen density","volume":"28","author":"Mansilla-Soto","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2025.06.007_bib111","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nm.3833","article-title":"Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes","volume":"21","author":"Caruana","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2025.06.007_bib112","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/s41591-024-02826-w","article-title":"T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy","volume":"30","author":"Ghilardi","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2025.06.007_bib113","article-title":"Efficient site-specific integration of large genes in mammalian cells via continuously evolved recombinases and prime editing","author":"Pandey","year":"2025922","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.jhep.2025.06.007_bib114","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/s41587-022-01527-4","article-title":"Drag-and-drop genome insertion of large sequences without double-strand DNA cleavage using CRISPR-directed integrases","volume":"41","author":"Yarnall","year":"2023","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jhep.2025.06.007_bib115","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2025.06.007_bib116","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2025.06.007_bib117","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002866","article-title":"NK cells enhance CAR T cell antitumor efficacy by enhancing immune\/tumor cells cluster formation and improving CAR T cell fitness","volume":"9","author":"Bachiller","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jhep.2025.06.007_bib118","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2300709","article-title":"Base-edited CAR7 T cells for relapsed T-cell acute lymphoblastic leukemia","volume":"389","author":"Chiesa","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2025.06.007_bib119","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/nbt.2678","article-title":"Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy","volume":"31","author":"Themeli","year":"2013","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jhep.2025.06.007_bib121","first-page":"5702","article-title":"Combining T-cell-specific activation and in vivo gene delivery through CD3-targeted lentiviral vectors","volume":"4","author":"Frank","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jhep.2025.06.007_bib122","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/s41587-023-02085-z","article-title":"In vivo human T cell engineering with enveloped delivery vehicles","volume":"42","author":"Hamilton","year":"2024","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jhep.2025.06.007_bib123","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nnano.2017.57","article-title":"In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers","volume":"12","author":"Smith","year":"2017","journal-title":"Nat nanotechnology"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827825022743?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827825022743?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:57:32Z","timestamp":1777510652000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827825022743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":130,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0168827825022743"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2025.06.007","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chimeric antigen receptor (CAR) T-cell therapy: Engineering immune cells to treat liver diseases","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2025.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}